Endovia Health Sciences, Inc.
No SEC Form 4 filings for $EDVA in the last 30 days.
See all $EDVA insider activity →Endovia Health Sciences, Inc. (EDVA) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. On August 25, 2026, Endovia Health Sciences, Inc. (the “Company”) sold and issued a total of 510,951 shares of common stock pursuant to that certain Securities Purchase Agreement dated September 19, 2025 with C/M Capital Master F
Endovia Health Sciences, Inc. (SBEV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On August 20, 2026, Endovia Health Sciences, Inc. (the “Company”) entered into an Employment Agreement (each, an “Agreement”) with each of Brady Cobb for his employment as Interim Chief Executive Officer of the Company and Mich
SPLASH BEVERAGE GROUP, INC. (SBEV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Splash Beverage Reports Second Quarter 2026 Results and Highlights Strategic Transformation Toward Endovia Health Sciences The Company’s loss from continuing operations declined by approximately 64% for the first six months of 2026 as cost reductions take hold FORT L
Over the past 7 days, alphai's AI scored 1 news story mentioning EDVA (Endovia Health Sciences, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent EDVA coverage spans corporate actions, earnings and technology.
Minor dilution and cash inflow; limited price impact expected.
Endovia Health Sciences, Inc. (SBEV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On August 20, 2026, Endovia Health Sciences, Inc. (the “Company”) entered into an Employment Agreement (each, an “Agreement”) with each of Brady Cobb for his employment as Interim Chief Executive Officer of the Company and Mich
SPLASH BEVERAGE GROUP, INC. (SBEV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Splash Beverage Reports Second Quarter 2026 Results and Highlights Strategic Transformation Toward Endovia Health Sciences The Company’s loss from continuing operations declined by approximately 64% for the first six months of 2026 as cost reductions take hold FORT L
SPLASH BEVERAGE GROUP, INC. (SBEV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On July 31, 2026, Splash Beverage Group, Inc. (the “Company”) entered into a Development and Collaboration Agreement (the “Collaboration Agreement”) with Lupvindol Biosciences Ltd. (“Lupvindol”), pursuant to which Lupvindol has
Splash Beverage Group Inc. (NYSE:SBEV) shares are trending on Friday. Shares of the Florida-based company climbed 64.10% to $0.57 after the bell on Thursday. The surge in the late trading session follows an intraday gain of 7.07% which closed the SBEV at $0.35, according to Benzinga Pro data. Splash Beverage Group, which engages in the manufacturing, distribution, marketing, and sale of various beverages, experienced an exceptionally elevated trading session on Thursday.
alphai scores every news story that mentions EDVA with an AI model for sentiment and relevance, and aggregates insider trades from Endovia Health Sciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Endovia Health Sciences, Inc. (EDVA) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. On August 25, 2026, Endovia Health Sciences, Inc. (the “Company”) sold and issued a total of 510,951 shares of common stock pursuant to that certain Securities Purchase Agreement dated September 19, 2025 with C/M Capital Master F
1 min readEndovia Health Sciences, Inc. (SBEV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On August 20, 2026, Endovia Health Sciences, Inc. (the “Company”) entered into an Employment Agreement (each, an “Agreement”) with each of Brady Cobb for his employment as Interim Chief Executive Officer of the Company and Mich
1 min readSPLASH BEVERAGE GROUP, INC. (SBEV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Splash Beverage Reports Second Quarter 2026 Results and Highlights Strategic Transformation Toward Endovia Health Sciences The Company’s loss from continuing operations declined by approximately 64% for the first six months of 2026 as cost reductions take hold FORT L
1 min readSPLASH BEVERAGE GROUP, INC. (SBEV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On July 31, 2026, Splash Beverage Group, Inc. (the “Company”) entered into a Development and Collaboration Agreement (the “Collaboration Agreement”) with Lupvindol Biosciences Ltd. (“Lupvindol”), pursuant to which Lupvindol has
6 min readSplash Beverage Group Inc. (NYSE:SBEV) shares are trending on Friday. Shares of the Florida-based company climbed 64.10% to $0.57 after the bell on Thursday. The surge in the late trading session follows an intraday gain of 7.07% which closed the SBEV at $0.35, according to Benzinga Pro data. Splash Beverage Group, which engages in the manufacturing, distribution, marketing, and sale of various beverages, experienced an exceptionally elevated trading session on Thursday.
5 min readSPLASH BEVERAGE GROUP, INC. (SBEV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EXHIBIT 99.1 Splash Beverage Group Expands CannEpil® Platform into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program Expansion broadens CannEpil into veterinary therapeutics as Splash advances its cannabinoid pharmaceutical development
4 min readSplash Beverage Group (NYSE American: SBEV) said it expanded its exclusive global CannEpil license to cover veterinary therapeutics. The company plans initial evaluation for companion-animal oncology and chronic pain, pursuing FDA Center for Veterinary Medicine INAD and Conditional Approval pathways. Splash will pay Argent BioPharma a 10% royalty on veterinary net revenues.
4 min readSPLASH BEVERAGE GROUP, INC. (SBEV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001553788 0001553788 2026-07-15 2026-07-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor
4 min readSplash Beverage Group (NYSE American: SBEV) said it settled legacy creditor claims totaling about $3.3 million for about $550,000 cash, expecting an approximate $2.75 million gain from debt extinguishment, subject to final accounting. Its board approved a 1-for-4 reverse stock split to support NYSE American minimum price compliance, reducing shares from ~25.2M to ~6.3M, effective July 27, 2026.
4 min readSPLASH BEVERAGE GROUP, INC. (SBEV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001553788 0001553788 2026-07-10 2026-07-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor
2 min read
